share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股变动声明-高管 Gibson Christopher
美股SEC公告 ·  08/30 16:28
Moomoo AI 已提取核心信息
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.
Recursion Pharmaceuticals的首席执行官Christopher Gibson已参与公司股票购买交易。2024年8月30日,Gibson以每股2.48美元的价格购买了Recursion Pharmaceuticals的5000股A类普通股。在此交易之后,Gibson直接持有公司的股份数增至762,656股。该交易目前被报告为进行中。
Recursion Pharmaceuticals的首席执行官Christopher Gibson已参与公司股票购买交易。2024年8月30日,Gibson以每股2.48美元的价格购买了Recursion Pharmaceuticals的5000股A类普通股。在此交易之后,Gibson直接持有公司的股份数增至762,656股。该交易目前被报告为进行中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息